Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Patheon Expands Offerings and Capacity at Milton Park, U.K. Facility

December 3, 2013

Patheon to Increase Solid Dose Capabilities at Its European Sites

(PRWEB) December 03, 2013

Patheon, a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, is increasing solid dose capabilities at its European sites. The latest investments are being made at the company’s Milton Park, U.K. facility. This stand-alone early development center will now offer automated capsule filling, instrumented tablet compression and tablet coating capabilities as well as increased manufacturing capacity. These upgrades will include DOE and QbD enabled equipment and expansion of time-saving disposable technologies to include tableting.

The Milton Park facility will now have the capability to manufacture supplies for up to Phase IIb studies with seamless transfers to Patheon’s recently upgraded Bourgoin, France, site for later stage clinical trials on compatible, scalable equipment. Milton Park will also now offer a wider range of dose forms: capsules, oral liquids, suspensions, tablets, microtablets and multiparticulates, as well as controlled-release coating technologies. This is in addition to established capabilities in high potency API handling, manual filling of up to approximately 10,000 capsules per batch, and the Quick to Clinic™ service offering for rapid results in early stage projects.

“This latest investment in Milton Park will enhance our flexible early development offerings with a wider range of dosage forms, technologies and capacity, all from one purpose-built facility,” said Jon Sutch, Ph.D., manager of formulation and clinical trials manufacture, based at Patheon’s Milton Park facility. “It positions Patheon as Europe’s strategic partner of choice for oral dose early development.”

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company's recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 15 locations, including 12 commercial contract manufacturing facilities and 9 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information, visit http://www.patheon.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/12/prweb11384849.htm


Source: prweb